Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

Baseline patient and tumor characteristics differentially affected type of death in the MA.17 placebo-controlled letrozole trial where cardiovascular death was not separately identified. The MA.27 trial allowed competing risks analysis of breast cancer (BC), cardiovascular, and other type (OT) of de...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Breast Cancer Res Treat
Egile Nagusiak: Chapman, Judith-Anne W., Shepherd, Lois E., Ingle, James N., Muss, Hyman B., Pritchard, Kathleen I., Gelmon, Karen A., Whelan, Timothy J., Elliott, Catherine, Goss, Paul E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363272/
https://ncbi.nlm.nih.gov/pubmed/27006189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3761-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak